Benzinga | Apr 13, 2021 07:09AM EDT

Apellis Provides 24-Month Update From Phase 1b Study Of Pegcetacoplan In Patients With Geographic Atrophy; Post Hoc Analysis Showed 46% Decrease In Mean Lesion Growth In Eight Patients

* Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007)

* Top-line data from Phase 3 DERBY and OAKS studies expected in Q3 2021

WALTHAM, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced 24-month data from the Phase 1b APL2-103 study of pegcetacoplan, an investigational targeted C3 therapy, in patients with advanced geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and low vision. GA is a leading cause of blindness that affects approximately five million people worldwide1,2 and has no treatment.